Abstract:The expression and methylation of p15INK4B gene and the expression of DNA methyltransferase genes (DNMTs) in the mononuclear cells (MNCs) from bone marrow of 54 cases with hematopoietic malignances were detected by using RT-PCR, Western blot, and methylation-specific PCR. Of the 54 patients, 10 cases were low-risk MDS, 10 cases were high-risk MDS, 10 cases were acute myeloid leukemia (AML), 10 cases were acute lymphocytic leukemia (ALL), 10 cases were chronic myeloid leukemia in chronic phase (CML-CP), and 4 cases were CML in blast phase (CML-BP). 10 normal persons were studied as nective controls. The results showed that the incidence of p15INK4B methylation in cells of high-risk MDS was higher than that in low-risk MDS (6/10 VS 1/10, P=0.003), and the p15INK4B methylation was found to be associated with the down-regulation of the expressions of p15INK4B gene on both mRNA (r=−0.734, p<0.001) and protein (r=−0.664, p=0.001)levels, which indicated that the silencing of p15INK4B gene was in conjunction with hypermethylation in MDS. The expressions of p15INK4B on mRNA level and protein levels were almost detected in the MNCs from bone marrow of normal persons without the p15INK4B methylation. We also found the expression of DNMT3A and DNMT3B in high-risk MDS (densitometry readings respectively: 0.624±0.146, 0.577±0.344) were higher than in low-risk MDS (densitometry readings respectively: 0.487±0.300, 0.338±0.290) (P<0.05). The expression of DNMT1 was higher in the groups of low-risk MDS, high-risk MDS, AL and CML-CP( densitometry readings respectively: 0.487±0.218, 0.697±0.243, 0.706±0.463 and 0.867±0.375) than in normal control (densitometry reading: 0.181±0.312)(P<0.05, figure listed bellow), which indicated that up-regulated DNMTS might contribute to the hypermethylation of p15INK4B, and the higher expressions of de novo methyltransferases DNMT3A and DNMT3B may be related to the disease progression of MDS. The methylation of p15INK4B was also detected in 9/20 of AL cases accompanied by over-expressions of DNMT1, DNMT3A, and DNMT3B (densitometry readings respectively: 0.706±0.463, 1.066±0.547, and 0.530±0.428). The methylation of p15INK4B was detected in 1 of 10 cases of CML-CP patients, but all be detected in 4 case of CML-BP patients. These results indicated that the hypermethylation of p15INK4B gene may be one of the most common genetic event in pathogenesis of high-risk MDS, acute leukemia, and blast phase of CML. Furthermore, DNMT3A and DNMT3B were substantially over-expressed in the bone marrow cells of these patients. which might play an important role in the transformation from MDS to acute leukemia.

Frequent Epigenetic Silencing of Proapoptotic Gene MAPK10 by Methylation in B Cell Lymphoma

Aberrant DNA Methylation Associated with Silencing BNIP3 Gene Expression in Haematopoietic Tumours

Study on Methylation of P15ink4b Gene and Its Mechanisms in Patients with Myelodysplastic Syndrome and Leukemia.

Global Characterization of Proteome and Lysine Methylome Features in EZH2 Wild-Type and Mutant Lymphoma Cell Lines.

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

Significance of Methylation State in SHP-1 Gene in B-cell Lymphoma

Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact

KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells

A Gene Panel, Including LRP12, Is Frequently Hypermethylated in Major Types of B-Cell Lymphoma

DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia.

Clinical significance of BCL2L10 expression and promoter methylation in myelodysplastic syndrome

DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.

Promoter Hypermethylation of PTPL1, PTPN6, DAPK, P16 and 5-Azacitidine Inhibits Growth in DLBCL.

Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.

Epigenetic Silencing of a Proapoptotic Cell Adhesion Molecule, the Immunoglobulin Superfamily Member IGSF4, by Promoter CpG Methylation Protects Hodgkin Lymphoma Cells from Apoptosis.

Loss of Promoter Methylation Contributes to the Expression of Functionally Impaired PRDM1β Isoform in Diffuse Large B-cell Lymphoma

Hypermethylation of PRDM1/Blimp-1 Promoter in Extranodal NK/T-cell Lymphoma, Nasal Type: an Evidence of Predominant Role in Its Downregulation

Prognostic Significance of DAPK Promoter Methylation in Lymphoma: A Meta-Analysis

Frequent Transcriptional Inactivation of Kallikrein 10 Gene by CpG Island Hypermethylation in Non-Small Cell Lung Cancer.